HighTower Advisors
NAVB

HighTower Advisors’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

HighTower Advisors’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-28,465
Closed -$48K – 3599
2021
Q3 		$48K Hold
28,465
– – ﹤0.01% 2940
2021
Q2 		$51K Buy
28,465
+13,000
+84% +$23K ﹤0.01% 2891
2021
Q1 		$33K Sell
15,465
-20,600
-57% -$48.2K ﹤0.01% 2870
2020
Q4 		$79K Buy
36,065
+4,450
+14% +$10.5K ﹤0.01% 2371
2020
Q3 		$84K Buy
31,615
+4,075
+15% +$14.6K ﹤0.01% 2256
2020
Q2 		$109K Buy
27,540
+12,450
+83% +$23.8K ﹤0.01% 2113
2020
Q1 		$13K Hold
15,090
– – ﹤0.01% 2110
2019
Q4 		$18K Buy
15,090
+2,000
+15% +$1.73K ﹤0.01% 2174
2019
Q3 		$11K Sell
13,090
-52
-0.4% -$32 ﹤0.01% 2304
2019
Q2 		$5K Buy
+13,142
New +$25.5K ﹤0.01% 2323
2019
Q1 		– Sell
-2,322
Closed -$4K – 2483
2018
Q4 		$4K Sell
2,322
-1,756
-43% -$7.24K ﹤0.01% 2162
2018
Q3 		$18K Hold
4,078
– – ﹤0.01% 2170
2018
Q2 		$18K Hold
4,078
– – ﹤0.01% 2116
2018
Q1 		$29K Sell
4,078
-3,170
-44% -$23.7K ﹤0.01% 2051
2017
Q4 		$49K Sell
7,248
-1,000
-12% -$8.46K ﹤0.01% 2109
2017
Q3 		$64K Sell
8,248
-650
-7% -$5.51K ﹤0.01% 2068
2017
Q2 		$93K Hold
8,898
– – ﹤0.01% 1975
2017
Q1 		$104K Buy
8,898
+595
+7% +$6.76K ﹤0.01% 1869
2016
Q4 		$107K Buy
8,303
+240
+3% +$3.81K ﹤0.01% 1771
2016
Q3 		$146K Buy
8,063
+90
+1% +$1.14K ﹤0.01% 1692
2016
Q2 		$84K Buy
7,973
+910
+13% +$17.9K ﹤0.01% 1609
2016
Q1 		$131K Buy
7,063
+250
+4% +$4.81K ﹤0.01% 1880
2015
Q4 		$178K Sell
6,813
-425
-6% -$14.8K ﹤0.01% 1777
2015
Q3 		$333K Sell
7,238
-16,119
-69% -$608K ﹤0.01% 1404
2015
Q2 		$752K Buy
23,357
+22,237
+1,985% +$646K 0.01% 868
2015
Q1 		$36K Buy
1,120
+275
+33% +$9.31K ﹤0.01% 1558
2014
Q4 		$32K Buy
+845
New +$23.2K ﹤0.01% 1532

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HighTower Advisors's NAVB Position: Q4 2021 in Review

HighTower Advisors sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2021, closing a stake of 28,465 shares — an estimated $48K sold.

HighTower Advisors first reported a position in NAVB in Q4 2014 and held it in 27 quarters. The position peaked at $752K in Q2 2015. 31 funds tracked by Wall St. Rank hold NAVB as of Q4 2021.

  • HighTower Advisors reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2021 after selling out during the quarter.
  • HighTower Advisors sold 28,465 Navidea Biopharmaceuticals Inc. shares in Q4 2021, an estimated $48K.
  • HighTower Advisors first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2014 and held it in 27 quarters.
  • HighTower Advisors's Navidea Biopharmaceuticals Inc. position peaked at $752K in Q2 2015.
  • 31 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2021.

Based on HighTower Advisors's 13F filing for Q4 2021, filed 10 Feb 2022.